← FDA DRUG APPROVALS

FDA ANDA · ANDA075281

DICLOFENAC SODIUM

Sponsor: AUROBINDO PHARMA USA

APPLICATION
ANDA075281
TYPE
ANDA
ORIGINAL APPROVAL
2002-02-12
LATEST ACTION
2025-12-31
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

DICLOFENAC SODIUMPrescription
DICLOFENAC SODIUM 75MG · TABLET, DELAYED RELEASE · ORAL
DICLOFENAC SODIUMPrescription
DICLOFENAC SODIUM 50MG · TABLET, DELAYED RELEASE · ORAL

Approval history

2025-12-31Labeling · Supplement 16 · standardAP
2024-11-21Labeling · Supplement 14 · standardAP
2021-04-28Labeling · Supplement 12 · standardAP
2021-03-29Labeling · Supplement 9 · standardAP
2016-05-09Labeling · Supplement 8 · standardAP
2014-11-28Labeling · Supplement 7 · standardAP
2010-03-19Labeling · Supplement 3AP
2007-12-20Labeling · Supplement 1AP
2002-02-12OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →